Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786792 | 1.00 | PIK3CA (0.51) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1785921 | 1.00 | PIK3CA (0.51) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1786393 | 0.95 | PIK3CA (0.54) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1786538 | 0.85 | CYP1A2 (0.47) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1787307 | 0.85 | CYP1A2 (0.47) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1788290 | 0.85 | CYP1A2 (0.47) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13893754 | 0.84 | GPR119 (0.42) | USP30GPR119PIK3CD | |
| SCHEMBL1785477 | 0.82 | CYP1A2 (0.48) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1788127 | 0.80 | PIK3CA (0.49) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1785493 | 0.80 | PIK3CA (0.49) | PIK3CACYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | PIK3CA 4190/4885CYP1A2 3643/4885CYP3A4 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.